AMRX

In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential for future equity dilution. Next, we will examine how this sizable shelf registration filing could influence Amneal’s investment narrative around growth, capital structure, and risk. Outshine the giants: these 19 early-stage AI stocks could fund your retirement. To own Amneal, you need to believe it can convert its broad generics, injectables, and biosimilars portfolio into steadily rising cash flow while managing debt. The new US$522.69 million shelf registration does not immediately change that core thesis, but it does sharpen the short term trade off between funding growth and the risk of equity dilution, on top of existing concerns about pricing pressure and leverage. The most relevant recent announcement here is Amneal’s very strong Q2 2026 report, with revenue of US$796.2 million, up 9.9% year on year, and higher full year guidance. Against that backdrop, the shelf registration gives the company an additional financing tool just as it is scaling new launches in injectables, biosimilars, and respiratory products, which are key to its near term growth story but also increase its capital needs. Yet even with this momentum, investors should be aware that pricing pressure in U.S. generics could... Read the full narrative on Amneal Pharmaceuticals (it's free!) Amneal Pharmaceuticals' narrative projects $3.9 billion revenue and $485.9 million earnings by 2029. This requires 7.8% yearly revenue growth and about a $328.5 million earnings increase from $157.4 million today. Uncover how Amneal Pharmaceuticals' forecasts yield a $21.00 fair value, a 20% upside to its current price. Some of the most optimistic analysts were assuming Amneal could reach about US$4.3 billion in revenue and US$481 million in earnings by 2029, but compared with the risk that higher leverage from Kashiv and ambitious biosimilar spending might strain margins if capacity is underused, you can see how opinions differ and why this new shelf filing could shift both narratives in different directions. Explore 3 other fair value estimates on Amneal Pharmaceuticals - why the stock might be worth over 2x more than the current price! Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. Our free Amneal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance. These stocks are moving-our analysis flagged them today. Act fast before the price catches up: Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution. Find 47 companies with promising cash flow potential yet trading below their fair value. The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AMRX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes. Looking ahead, the industry is supported by tailwinds such as the role of AI in streamlining drug development (reverse engineering complex formulations) and manufacturing efficiency (optimize processes and remove inefficiencies). Governments and insurers' focus on reducing drug costs can also boost generics' adoption. However, headwinds include escalating pricing pressure from large buyers like pharmacy chains and healthcare distributors as well as evolving regulatory hurdles. The 4 generic pharmaceuticals stocks we track reported a very strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.6%. While some generic pharmaceuticals stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 3.9% since the latest earnings results. Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ:AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market. Amneal reported revenues of $796.2 million, up 9.9% year on year. This print exceeded analysts’ expectations by 3.6%. Overall, it was a very strong quarter for the company with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. Amneal pulled off the biggest analyst estimate beat and highest full-year guidance raise in the group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 6.4% since reporting and currently trades at $17.88. Is now the time to buy Amneal? Access our full analysis of the earnings results here, it’s free. Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. Amphastar Pharmaceuticals reported revenues of $183.9 million, up 5.4% year on year, outperforming analysts’ expectations by 2%. The business had an exceptional quarter with a beat of analysts’ EPS estimates. The market seems happy with the results as the stock is up 8.5% since reporting. It currently trades at $21.50. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis of the earnings results here, it’s free. With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments. ANI Pharmaceuticals reported revenues of $266 million, up 25.9% year on year, exceeding analysts’ expectations by 2.4%. Still, it was a mixed quarter as it posted full-year revenue guidance slightly missing analysts’ expectations. ANI Pharmaceuticals delivered the fastest revenue growth but had the weakest full-year guidance update in the group. As expected, the stock is down 11.8% since the results and currently trades at $72.85. Read our full analysis of ANI Pharmaceuticals’s results here. Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ:VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide. Viatris reported revenues of $3.76 billion, up 4.9% year on year. This result surpassed analysts’ expectations by 2.2%. Overall, it was a strong quarter as it also recorded a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates. Viatris had the slowest revenue growth of the whole group. The stock is down 5.8% since reporting and currently trades at $16.63. Read our full, actionable report on Viatris here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which rose 157% from $39.7 million a year ago and came above the Zacks Consensus Estimate of $95 million. Results reflected continued DefenCath utilization among large outpatient dialysis customers and a full-quarter contribution from the acquired Melinta portfolio. Management also lifted its full-year EBITDA outlook following the better-than-expected second-quarter 2026 results. The stock gained 14.7% on Thursday following the earnings release. DefenCath remained the largest revenue source in the quarter, generating $66.1 million in sales. Management said continued utilization by large outpatient dialysis customers supported performance, while the year-over-year increase was driven largely by the onboarding of a large dialysis organization in mid-2025. CorMedix also signed a multi-year commercial supply agreement for DefenCath with another large dialysis organization, bringing its commercial supply agreements to all five of the top U.S. dialysis providers. The customer placed an initial order and is set to begin a pilot in the third quarter, giving CRMD another potential avenue for broader DefenCath utilization. The acquired Melinta portfolio contributed $35.8 million to second-quarter revenues. The Melinta acquisition closed in August 2025, so the second quarter of 2025 included revenues only from DefenCath, making the year-over-year revenue comparison structurally different. Shares of CorMedix have plunged 30% so far this year against the industry’s 5.8% growth. Image Source: Zacks Investment Research Total operating expenses were $34.2 million in the second quarter, up about 87% from $18.3 million a year earlier. The increase mainly reflected a full quarter of expenses from the Melinta acquisition and the combined company's larger cost structure. R&D expenses rose significantly to $6.7 million from $2.4 million, driven primarily by higher personnel and clinical study services supporting ongoing programs. Selling and marketing expenses increased about 95% to $12.4 million, while general and administrative expenses rose about 59% to $15.1 million. CorMedix ended the second quarter with cash and cash equivalents of $256.7 million, excluding restricted cash, up from $178.1 million at the end of the first quarter of 2026. Management believes its existing resources are sufficient to fund operations for at least 12 months from the issuance of the company’s second-quarter Form 10-Q. Management maintained its full-year 2026 consolidated revenue guidance of $325-$345 million. It also reiterated DefenCath's revenue guidance of $175-$195 million, with management noting that the franchise was tracking toward the middle to upper end of that range. CorMedix raised its full-year adjusted EBITDA guidance to $125-$140 million. Management also said recent customer contract amendments covering third- and fourth-quarter 2026 pricing, and in some cases 2027 pricing and volume commitments, improved visibility into utilization through year-end. CorMedix Inc price-consensus-eps-surprise-chart | CorMedix Inc Quote CorMedix, with partner Mundipharma, expects to submit a supplemental new drug application for Rezzayo in prophylaxis of invasive fungal disease in the third quarter of 2026. The phase III ReSPECT study of the drug met its primary FDA endpoint of fungal-free survival at day 90 and demonstrated non-inferiority versus the standard antifungal regimen. If the filing is accepted for review, the company expects FDA action in the first half of 2027. CorMedix is also advancing its phase III DefenCath study in patients with total parenteral nutrition, having submitted a protocol amendment to narrow certain exclusion criteria. The company continues to expect study completion in 2028. CorMedix currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX, Repligen RGEN and AC Immune ACIU. AMRX and RGEN currently sport a Zacks Rank #1 (Strong Buy) each, while ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, earnings estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, earnings estimates increased from $1.12 to $1.21 for 2027. AMRX shares have risen 37% year to date. Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%. Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62. RGEN shares have lost 2.2% year to date. Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%. Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have plunged 18.2% year to date. AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CorMedix Inc (CRMD) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report AC Immune (ACIU) : Free Stock Analysis Report AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. After a very strong three year run for Amneal Pharmaceuticals, the stock no longer looks obviously cheap, and the latest valuation checks suggest investors should be careful about assuming further easy gains from here. Amneal Pharmaceuticals has delivered a very large 345.7% return over the past three years, which sets a high bar for future returns to justify the current price. Expectations around Amneal Pharmaceuticals’ ability to sustain cash generation and manage its balance sheet can support the current share price, while any setback in profitability or leverage could quickly challenge that valuation. The stock only passes 2 of 6 broad valuation checks, which points to a company that screens more expensive than cheap on the overall framework. The issue now is whether Amneal Pharmaceuticals’ share price fairly reflects its fundamentals after this strong run, or if expectations have moved too far ahead of the business. Amneal Pharmaceuticals delivered 134.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. The P/E ratio is a useful cross check for Amneal Pharmaceuticals because it ties the current share price directly to reported earnings. Amneal trades on a P/E of about 37.1x, which is well above the Pharmaceuticals industry average of roughly 14.9x and also higher than the peer group average near 20.4x. A tailored fair P/E ratio for Amneal Pharmaceuticals is estimated at about 34.1x once factors such as business profile and risk are taken into account. That is not far below the actual 37.1x multiple, so the stock does not screen as dramatically expensive or cheap on this measure. The small premium to the fair ratio suggests that a lot of good news is already in the price, so investors might want to be confident that current earnings power can at least be maintained. Overall, Amneal Pharmaceuticals appears roughly fairly valued on its P/E multiple, with the share price sitting close to the level implied by this framework. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Amneal Pharmaceuticals pick up where the P/E discussion leaves off and spell out which paths for future growth, margins and earnings would make the stock look meaningfully higher or lower than it does today. Rather than stopping at a single output from a ratio or model, they lay out the business outcomes that figure rests on so you can see what would need to happen and track whether that picture still holds over time on the Community page. Community views on Amneal Pharmaceuticals sit on a clear fault line, with one side seeing meaningful upside potential and the other arguing most of the story is already reflected in the price. Bull case: 20% undervalued Read the full Bull Case to see why Amneal Pharmaceuticals could be undervalued Bear case: roughly fairly valued Read the full Bear Case to see why Amneal Pharmaceuticals could be overvalued Do you think there's more to the story for Amneal Pharmaceuticals? Head over to our Community to see what others are saying! Amneal Pharmaceuticals now looks about right on its P/E based assessment, which means the stock no longer stands out as clearly cheap or clearly expensive on the available checks. The big recent move in the share price has pulled forward a lot of optimism, so the key question is whether current earnings power and balance sheet management can hold up well enough to support that premium. The crux of the bull versus bear debate is how reliably Amneal can sustain profitability in a competitive generics market while handling its leverage. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AMRX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterizes the current period as the most transformative in company history, driven by a deliberate shift toward complex, high-value medicines over legacy oral solids. Performance attribution is centered on the Affordable Medicines segment, where demand for transdermal patches surged following revised FDA guidance, prompting a strategic capacity tripling. The pending Kashiv acquisition is framed as a critical pivot to becoming a fully integrated global biosimilar player, capturing higher economics by controlling development through commercial supply. Operational resilience was tested by severe flooding at a Gujarat facility; however, management expects limited impact on select products with operations resuming within weeks. Strategic positioning in Specialty is gaining traction as CREXONT adoption shifts toward general neurologists, who write 80% of Parkinson's prescriptions. The company's Brookhaven site selection for the FDA's PreCheck Pilot Program validates its U.S. manufacturing quality and readiness for upcoming sterile injectable expansion. The 2026 revenue outlook was raised by $50 million to $3.1 billion - $3.2 billion, assuming high single-digit growth in both Specialty and Affordable Medicines. Guidance includes a $20 million estimated negative impact from the India facility flood, offset by higher profitability and lower interest expense from debt repricing. CapEx expectations increased from $110 million to $150 million to capitalize on immediate market demand for Women's Health products and U.S. injectable expansion. Management anticipates the Kashiv transaction will provide $400 million to $500 million in financial benefits via tax incentives and the elimination of profit-sharing obligations. The long-term strategy targets $1 billion to $2 billion in new revenue from the Affordable Medicines pipeline through 2030, supported by 12 to 15 high-value complex ANDA filings planned for the current year. The Gujarat flooding represents a localized operational risk, though management mitigated this by confirming all employees are safe and the the recent flood at the India facility is estimated to have a $20 million negative impact. A successful repricing of the $2.084 billion Term Loan B reduced interest expense by 50 basis points, yielding $12 million in annual savings. Management flagged drug shortages in the U.S. as a strategic opportunity, positioning their domestic manufacturing footprint as a solution for supply chain resiliency. The Kashiv acquisition introduces a clear deleveraging path, with a management target to bring net leverage below 3x by 2028. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Lanreotide remains on track for a Q3 2026 launch with conservative figures included in current guidance. The XOLAIR biosimilar launch is expected very late in the year or may spill into January 2027, with zero revenue currently modeled for 2026. Management is pursuing a 'full basket' strategy, expecting all strengths to be approved by year-end to capture a larger market share. While 2026 revenue is not meaningful, iohexol is projected to become a $50-plus million opportunity starting in 2027 as capacity expands. The company is shifting its M&A focus toward Specialty assets, specifically targeting CNS and oncology to leverage existing commercial infrastructure. Management intends to use excess cash flow to add branded pipeline assets internally and externally starting next year. The partnership is progressing well with plans to have operational plants by 2029 and 2030 to support global supply. Amneal holds exclusive commercial rights in specific markets like India and Egypt, which are currently being evaluated for launch potential.

Amneal Pharmaceuticals AMRX reported second-quarter 2026 adjusted earnings of 30 cents per share, which beat the Zacks Consensus Estimate of 24 cents. Earnings increased 20% year over year, driven by strong performance across the company’s three business segments. Total revenues of $796 million in the second quarter of 2026 increased 10% year over year. The top line also beat the Zacks Consensus Estimate of $768 million. The upside reflected strong growth across Affordable Medicines and Specialty and a favorable product mix. Despite better-than-expected results, Amneal shares were down 3.1% yesterday following the announcement. The stock has rallied 46.8% so far this year against the industry’s decline of 2.4%. Image Source: Zacks Investment Research Affordable Medicines' second-quarter revenues were $490 million, up 13% year over year. Segment growth was driven by strength in the company’s broad-based complex portfolio, including Women's Health products, injectables and higher naloxone sales. Specialty’s second-quarter revenues of $149 million grew 17% year over year, driven by continued momentum in Crexont, Unithroid and Brekiya. Sales of all these products came in ahead of management’s expectations. AvKARE net revenues of $157 million declined 4% year over year as growth in the government channel was offset by a decline in the low-margin distribution channel during the quarter. Adjusted research and development expenses decreased 17.7% year over year to $38.2 million in the second quarter of 2026, while adjusted selling, general and administrative expenses surged 19.6% year over year to $134.9 million. As of June 30, 2026, Amneal had cash and cash equivalents worth $127.6 million compared with $197.7 million as of March 31, 2026. Amneal raised its 2026 net revenue guidance from $3.05-$3.15 billion to $3.10-$3.20 billion. The company now expects adjusted EBITDA of $750 million to $780 million, up from its earlier projection of $740 million to $770 million. Adjusted EPS is now expected to be in the range of 96 cents to $1.06, up from its earlier estimate of 95 cents to $1.05. In April 2026, Amneal announced a definitive agreement to acquire privately held biotech company Kashiv BioSciences for up to $1.10 billion. The transaction is expected to be closed in the second half of 2026, subject to customary closing conditions. The pending Kashiv acquisition is expected to create a fully integrated biosimilars platform spanning development, clinical execution, regulatory capabilities and commercial supply. The combined pipeline will include more than 20 biosimilar programs. Management believes biosimilars will become a durable long-term growth pillar, further diversifying the company's portfolio alongside its Affordable Medicines, Specialty and AvKARE businesses while strengthening its competitive position in the global biologics market. AMNEAL PHARMACEUTICALS, INC. price-consensus-eps-surprise-chart | AMNEAL PHARMACEUTICALS, INC. Quote Amneal currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.30, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have lost 4.2% year to date. Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%. Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.03, while estimates for 2027 have increased from $2.43 to $2.44 during the same time. RGEN shares have declined 12.3% year to date. Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%. Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 151.7% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +25.00%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.17 per share when it actually produced earnings of $0.27, delivering a surprise of +58.82%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Amneal, which belongs to the Zacks Medical - Drugs industry, posted revenues of $796.2 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.70%. This compares to year-ago revenues of $724.51 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Amneal shares have added about 51.6% since the beginning of the year versus the S&P 500's gain of 6.9%. While Amneal has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Amneal was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.27 on $820.85 million in revenues for the coming quarter and $1.00 on $3.12 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. 4D Molecular Therapeutics, Inc. (FDMT), another stock in the same industry, has yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $1.04 per share in its upcoming report, which represents a year-over-year change of -6.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. 4D Molecular Therapeutics, Inc.'s revenues are expected to be $0.02 million, up 100% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report 4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better. Amneal reported strong Q2 results, with revenue up 10% to $796 million, adjusted EBITDA up 12% to $206 million and adjusted EPS up 20% to $0.30. Growth in affordable medicines and specialty products offset a decline in AvKARE distribution. The company raised its 2026 outlook to $3.1 billion–$3.2 billion in revenue, $750 million–$780 million in adjusted EBITDA and $0.96–$1.06 in adjusted EPS, despite an estimated $20 million flood-related impact in India. Amneal is advancing major growth initiatives, including the pending Kashiv acquisition, expanded biosimilar capabilities and manufacturing investments in patches and injectables. Management expects more than 20 biosimilar programs and six commercialized biosimilars by next year. 3 Lesser-Known Healthcare Names With Major Upside in Store Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix. Adjusted EBITDA rose 12% to $206 million, while adjusted diluted earnings per share increased 20% to $0.30. Adjusted gross margin expanded 60 basis points year over year to 46.2%, which Chief Financial Officer Tasos Konidaris attributed to mix improvements and operating efficiencies. → Why SK hynix Could Be the Best AI Chip Stock to Buy Now 6 reasons to buy Teva Pharmaceuticals stock sooner than later “The second quarter played out as expected, with revenue growth accelerating and broad-based momentum building across our business,” Konidaris said during the company’s earnings call. Revenue in Amneal’s affordable medicines segment increased 13% to $490 million. The company said the result reflected demand across its complex product portfolio, including women’s health products, injectables and naloxone. New launches contributed $45 million to second-quarter revenue growth, including recently launched ophthalmology and urology products. → 3 Value ETFs to Consider as Growth Stocks Lag Behind Specialty revenue increased 17% to $149 million, driven by CREXONT, Unithroid and Brekiya. Co-CEO and President Chirag Patel said CREXONT, a Parkinson’s therapy, continues to gain traction, with approximately 80% of prescriptions coming from general neurologists. He said the company aims to position the therapy as a first-line treatment. Amneal also discussed Phase IV data for CREXONT. Co-CEO Chintu Patel said an open-label study showed patients converting to CREXONT had three or more hours of “good on time” per day compared with RYTARY and other carbidopa/levodopa therapies, alongside improvement in symptom control. The company plans to begin another Phase IV study in the fourth quarter involving recently diagnosed, treatment-naive Parkinson’s disease patients. → 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest? AvKARE revenue fell 4% to $157 million, as government-channel growth was offset by lower-margin distribution business, according to Konidaris. The company said it remains focused on its government and institutional channel opportunities. Amneal raised its 2026 revenue forecast by $50 million to a range of $3.1 billion to $3.2 billion. It now expects adjusted EBITDA of $750 million to $780 million, an increase of $10 million from its previous outlook, and adjusted EPS of $0.96 to $1.06, up one cent at both ends of the prior range. The guidance includes an estimated $20 million negative impact from severe rainfall and flooding in Gujarat, India, which affected one of Amneal’s facilities. Chintu Patel said all employees were safe and accounted for, and the company expects a limited impact on a select number of products. Operations at the affected site are expected to resume within the next few weeks. Amneal increased its capital-expenditure expectations to between $110 million and $150 million, citing opportunities in women’s health products and U.S. injectable expansion. It maintained its operating cash flow guidance. The company also said it repriced its $2.4 billion Term Loan B due in 2032, lowering its interest expense by 50 basis points. Konidaris said the refinancing is expected to produce approximately $12 million in annual interest savings. Management continued to emphasize the pending acquisition of Kashiv, which it expects to close in the coming weeks following a shareholder vote and satisfaction of closing conditions. The deal is intended to add biologics development and manufacturing capabilities to Amneal’s commercial platform. Chintu Patel said Kashiv’s drug-substance capacity is expected to expand from approximately 26,000 liters by the end of 2026 to about 75,000 liters by 2028. The combined company expects to have a pipeline of more than 20 biosimilar programs and cited opportunities involving Xolair, Orencia, Cimzia and Stelara. Chirag Patel said Amneal currently markets ALYMSYS, Releuko and Fylnetra and expects to launch biosimilars for Prolia and Xgeva. He said a Xolair biosimilar could launch very late this year or potentially in early 2027, though no Xolair contribution is included in 2026 guidance. The company expects to commercialize six biosimilars by next year. Konidaris said the Kashiv transaction is expected to generate $400 million to $500 million in financial benefits through tax and local incentives and the elimination of milestone and profit-sharing obligations. Amneal expects net leverage to fall below three times by 2028. Management said it is expanding manufacturing capacity for estrogen transdermal patches following increased demand after revised FDA guidance late last year. Chirag Patel said the company plans to triple patch capacity by next year. Amneal is also expanding capacity for lidocaine patches and U.S. sterile injectables. The company expects a potential approval and launch of lanreotide during the third quarter, with a conservative revenue contribution included in its forecast. Chirag Patel described lanreotide as a complex drug-device combination with multiple barriers to entry. Amneal also cited recent approvals for romidepsin, additional iohexol strengths and ready-to-use sodium bicarbonate. The company expects additional iohexol approvals by year-end and said the product could represent a $50 million-plus opportunity over time, with more substantial revenue contribution anticipated beginning in 2027. Looking ahead, Amneal plans to file 12 to 15 high-value complex abbreviated new drug applications this year, including two metered-dose inhalation products. The company also said its Brookhaven, New York, facility was selected as one of seven companies in the FDA’s PreCheck pilot program, which is designed to support earlier engagement on facility readiness and strengthen domestic pharmaceutical manufacturing capacity. Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments. Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Amneal Pharmaceuticals Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

This article first appeared on GuruFocus. Total Net Revenue: $796 million, up 10% year-over-year. Adjusted EBITDA: $206 million, up 12% year-over-year. Adjusted EPS: $0.30, up 20% year-over-year. Adjusted Gross Margin: 46.2%, up 60 basis points year-over-year. Affordable Medicines Revenue: $490 million, up 13%. Specialty Revenue: $149 million, up 17%. AvKARE Revenue: $157 million, down 4%. New Product Launches Contribution: Added $45 million to second quarter revenue growth. Full Year 2026 Revenue Guidance: Increased to $3.1 billion to $3.2 billion. Full Year 2026 Adjusted EBITDA Guidance: Raised to $750 million to $780 million. Full Year 2026 Adjusted EPS Guidance: Increased to $0.96 to $1.06. Full Year 2026 CapEx Guidance: Increased to approximately $150 million. Warning! GuruFocus has detected 6 Warning Sign with AMRX. Is AMRX fairly valued? Test your thesis with our free DCF calculator. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Amneal Pharmaceuticals Inc (NASDAQ:AMRX) delivered strong Q2 2026 results with revenue of $796 million, adjusted EBITDA of $206 million, and adjusted EPS of $0.30, marking the seventh consecutive year of top and bottom-line growth. The pending acquisition of Kashiv will create a fully integrated global biosimilar platform, with a pipeline of over 20 programs and a clear path to capturing $400-$500 million in financial benefits. Specialty products CREXONT and Brekiya continue to show strong uptake, with CREXONT gaining traction as a potential first-line Parkinson's treatment and Brekiya addressing unmet needs in migraine and cluster headache. The affordable medicines pipeline is robust, with high-value launches like lanreotide (expected in Q3), iohexol, and romidepsin, supported by complex manufacturing and strong customer relationships. Operational excellence is highlighted by the FDA PreCheck pilot program selection for the Brookhaven site, expansion in women's health transdermal patches, and a 50 basis point reduction in Term Loan B interest expense, saving $12 million annually. A severe flood at a manufacturing facility in Gujarat, India, is expected to cause a limited impact on select products and an estimated $20 million negative impact on 2026 guidance. The Kashiv acquisition, while promising, introduces integration risks and requires significant capital expenditure, with CapEx guidance raised to $150 million to capitalize on near-term opportunities. AvKARE revenue declined 4% in Q2, driven by weakness in the low-margin distribution business, partially offset by growth in the government channel. The launch of the Xolair biosimilar is delayed to late 2026 or early 2027, with no revenue contribution expected in the current year, potentially impacting near-term biosimilar growth. Tariff and regulatory uncertainties from recent administration announcements pose potential risks to the industry, though Amneal's US manufacturing footprint may mitigate some impact. Here are the key highlights from the Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q2 2026 earnings call, presented as summarized Q&A pairs. Q: Can you provide an update on the timing for the lanreotide and Xolair biosimilar launches, and what is included in the 2026 guidance for these? A: (Chirag Patel, Co-CEO) We are very optimistic about a lanreotide launch in Q3 of this year. We have included a conservative forecast for it in our guidance. For Xolair, we expect a launch very late in the year or potentially spilling into early next year, so nothing is included for Xolair in our 2026 guidance. Q: What is the potential market opportunity for the iohexol product, especially with the new SKUs approved, and how long do you expect limited competition? A: (Chirag Patel, Co-CEO) Iohexol is a very complex product requiring strong supply chain control. We are excited about the new SKU approvals and expect to complete the full basket of strengths by next year. We view this as a $50 million-plus opportunity, potentially more, and we have secured a very good supply chain to capitalize on the full market potential in 2027. Q: What are the key trends driving the strong uptake for CREXONT, and what is your strategy for it? A: (Chirag Patel, Co-CEO) We are seeing 80% of new prescriptions coming from general neurologists, which was not the case for RYTARY. This is significant because general neurologists write 80% of all Parkinson's prescriptions. The Phase IV data is very compelling, showing patients gaining three or more hours of "good on time." Our goal is to make CREXONT a first-line therapy to replace immediate-release products. Q: How large is the market potential for estrogen patches following the revised FDA guidance, and how is Amneal positioned to capture it? A: (Chirag Patel, Co-CEO) There is huge demand for estrogen patches, which we manufacture in New Jersey. We are expanding our capacity 24/7 and have secured equipment to triple our capacity by next year. This represents a huge addition to revenue. Combined with other high-demand products like lidocaine patches and ophthalmics, we believe the affordable medicines business could add $1 billion to $2 billion in new revenue from now to 2030. Q: What are your top priorities for the biosimilars business and the Kashiv acquisition over the next 6-12 months? A: (Chirag Patel, Co-CEO) Our immediate focus is on integrating Kashiv and advancing our pipeline for key molecules like abatacept (Orencia), Nplate, and Cimzia. Our goal is to enhance R&D capabilities to potentially file three or four biosimilars a year. We are also looking into new drug-device combinations within biologics, similar to a 505(b)(2) strategy, to expand beyond just biosimilars. For the complete transcript of the earnings call, please refer to the full earnings call transcript.